Últimas noticias sobre Natera (NASDAQ:NTRA) Bolsa

Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Natera Inc

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">initiated a short position in the company</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">analyst estimates of $2.951 billion</a>. Morgan Stanley maintained an Equal-Weight rating and lowered the <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $70 to $38</a>.</li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">steered investors toward</a> quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is<a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener"> successfully operating in orbit</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) stock lost 9.51% last week despite Guggenheim <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast</a> from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock decreased 9.27%  after the company issued FY24 revenue guidance <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">below the previous estimate</a>.</li>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) stock fell 9.22% after the company issued FY25 guidance with <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">its midpoint below estimates</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares declined 8.89% after Moderna issued 2025 revenue <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">guidance below analyst estimates</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">Medicare drug price negotiations</a>.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">Unified Patent Court (UPC) in Munich, Germany</a>.</li>
</ol>
Photos courtesy: Shutterstock

Equities

Large Cap

News

Short Sellers

Movers

Trading Ideas

BMRN

BNTX

FTAI

ICLR

MRNA

NTRA

RGTI

RKLB

SNAP

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="586" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--1024x586.jpg" alt="" class="wp-image-4711" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--1024x586.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--300x172.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40--768x440.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16084402/60-40-.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The End Of The 60/40 Portfolio&nbsp;</h2>
For years, a common investing approach was the 60/40 portfolio: 60% in stocks, and 40% in bonds. The idea behind it was simple: bonds were expected to outperform when stocks underperformed, and vice-versa. But as Tatiana Darie of Bloomberg pointed out yesterday (&#8220;<a href="https://www.zerohedge.com/markets/shifting-correlations-unleash-market-havoc" target="_blank" rel="noreferrer noopener nofollow">Shifting Correlations Unleash Market Havoc</a>&#8220;), that is no longer the case:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">Whether&nbsp;good&nbsp;or bad, shifting correlations are poised to wreak havoc on cross-asset strategies, and hedging assumptions will likely need to change. In the current environment, bonds are no longer proving to be a shield from stock losses.&nbsp;Jim Bianco&nbsp;of Bianco Research says the reason to hold bonds is changing, calling the days of the 60/40 portfolio&nbsp;"over."
It also means that trading might require a more creative and active approach that goes beyond traditional (and stale) assumptions.
</blockquote>
<h2 class="wp-block-heading">Moving Beyond Traditional (And Stale) Assumptions</h2>
As it happens, we developed an approach that moves beyond traditional assumptions. Specifically, it moves beyond the assumption that asset allocation is useful at all. The 60/40 portfolio, and other forms of asset allocation, deliberately put you in asset classes expected to perform badly. Why not put your money in assets you expect will do well? If you&#8217;re worried about downside risk, you can hedge with options. That&#8217;s essentially our approach, <a href="https://portfolioarmor.com/" target="_blank" rel="noreferrer noopener nofollow">The Hedged Portfolio Method</a>. 
<h2 class="wp-block-heading">The Hedged Portfolio Method&nbsp;</h2>
Here&#8217;s how our method works, in a nutshell:&nbsp;
<ol>
<li>Our system estimates 6-month returns for each security with options traded on it in the U.S. In addition to stocks, this universe of securities includes bond and commodity ETFs and even inverse ETFs. Our system is completely agnostic when it comes to asset class.&nbsp;</li>
<li>Next, our system finds optimal hedges for each security, and calculates their cost.&nbsp;</li>
<li>We subtract the hedging costs in 2. from the estimated returns in 1. and rank the securities by expected return, net of hedging cost.&nbsp;</li>
<li>The names that come to the top of the list in 3. are our top names. We buy and hedge a handful of them.&nbsp;</li>
</ol>
There are some additional steps, such as using a tightly collared &#8220;cash substitute&#8221; to minimize cash and boost returns, but that&#8217;s the gist of it.&nbsp;
<h2 class="wp-block-heading">Precisely Limiting Your Risk</h2>
One advantage of our approach is that you can precisely limit your risk. Don&#8217;t want to risk a decline of more than 17% over the next 6 months? Our system will hedge it so you don&#8217;t. Much different from putting 40% of your money in bonds and hoping for the best.&nbsp;
<h2 class="wp-block-heading">A Real World Example&nbsp;</h2>
Here&#8217;s a portfolio our system created for an investor in July of last year. This was for an investor unwilling to risk a decline of more than 20% over the next 6 months. This one included&nbsp;American Superconductor Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>),&nbsp;Abercrombie &amp; Fitch Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>),&nbsp;Constellation Energy Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>),&nbsp;Dell Technologies, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>),&nbsp;Navios Maritime Partners LP&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMM#NYSE">NMM</a>),&nbsp;Natera, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), and&nbsp;Powell Industries, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>).
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="776" height="717" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio.jpg" alt="" class="wp-image-4712" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio.jpg 776w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio-300x277.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085209/1-Portfolio-768x710.jpg 768w" sizes="(max-width: 776px) 100vw, 776px" /></figure>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="778" height="598" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio.jpg" alt="" class="wp-image-4713" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio.jpg 778w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio-300x231.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085242/2-Portfolio-768x590.jpg 768w" sizes="(max-width: 778px) 100vw, 778px" /></figure>
Here is how that portfolio performed over the next six months:&nbsp;
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="800" height="623" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1.jpg" alt="" class="wp-image-4714" style="width:800px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1.jpg 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1-300x234.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085327/Tracked-Portfolio-1-768x598.jpg 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="800" height="319" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2.jpg" alt="" class="wp-image-4715" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2.jpg 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2-300x120.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085411/Tracked-Portfolio-2-768x306.jpg 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
You can find an interactive version of that chart&nbsp;<a href="https://portfolioarmor.com/front_tests/5837">here</a>. And you can see how hundreds of other hedged portfolios have done&nbsp;<a href="https://portfolioarmor.com/performance-tracking-portfolios">here</a>.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and create hedged portfolios on <a href="https://portfolioarmor.com/" target="_blank" rel="noreferrer noopener nofollow">our website</a>. You can also follow Portfolio Armor on X <a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to <a href="https://portfolioarmor.substack.com/">our trading Substack</a> using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085726/Widget-5.jpg" alt="" class="wp-image-4716" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085726/Widget-5.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/16085726/Widget-5-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

Personal Finance

AMSC

DELL

POWL

The End Of The 60/40 Portfolio

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) from $108 to $124. JP Morgan analyst Kian Abouhossein maintained a Neutral rating. Morgan Stanley shares closed at $135.81 on Thursday. <a href="https://www.benzinga.com/quote/MS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group slashed Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) price target from $53 to $51. Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating. Bank of America shares closed at $46.64 on Thursday. <a href="https://www.benzinga.com/quote/BAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised the price target for Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) from $25 to $30. Barrington Research analyst Alexander Paris maintained an Outperform rating. Universal Technical Institute shares closed at $26.00 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim increased the price target for Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) from $170 to $200. Guggenheim analyst Subbu Nambi maintained a Buy rating. Natera shares closed at $168.50 on Thursday. <a href="https://www.benzinga.com/quote/NTRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) price target from $208 to $200. Wells Fargo analyst Joe Quatrochi maintained an Equal-Weight rating. Texas Instruments shares settled at $187.37 on Thursday. <a href="https://www.benzinga.com/quote/TXN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) price target from $35 to $41. Northland Capital Markets analyst Michael Latimore maintained an Outperform rating. Symbotic shares closed at $31.82 on Thursday. <a href="https://www.benzinga.com/quote/SYM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays increased NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) price target from $160 to $175. Barclays analyst Blayne Curtis maintained an Overweight rating. Nvidia shares closed at $133.57 on Thursday.  <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from $23 to $30. Piper Sandler analyst David Amsellem maintained an Overweight rating. Teva Pharmaceutical shares settled at $21.68 on Thursday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Planet Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) price target from $90 to $100. JP Morgan analyst Rahul Krotthapalli maintained an Overweight rating. Planet Fitness shares closed at $105.98 on Thursday. <a href="https://www.benzinga.com/quote/PLNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods cut KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) price target from $85 to $76. Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained a Market Perform rating. KB Home shares closed at $68.25 on Thursday. <a href="https://www.benzinga.com/quote/KBH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43049593/slb-jb-hunt-transport-and-3-stocks-to-watch-heading-into-friday">SLB, J.B. Hunt Transport And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Price Target

Markets

Analyst Ratings

NVDA

PLNT

TEVA

Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $170 to $200.

Guggenheim Maintains Buy on Natera, Raises Price Target to $200

Events

Natera To Provide Roadmap And Outlook At  J.P. Morgan Healthcare Conference

General

Natera shares are trading higher after the company reported preliminary FY24 financial results.

2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook
Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Natera Reports Preliminary 2024 Results: $1.7B In Annual Revenue (+56% YoY), $472M In Q4 Revenue (+52% YoY), And $86.3M In Positive Cash Flow For 2024

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $167.71, a high estimate of $200.00, and a low estimate of $135.00. Observing a 18.41% increase, the current average has risen from the previous average price target of $141.64. 
<img src="https://www.benzinga.com/files/images/story/2025/1736542810_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Natera. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Natera's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Natera's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Natera analyst ratings.</a>
<h2>Get to Know Natera Better</h2>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Natera: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Natera displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 63.9%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Natera's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.18% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Natera's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.68% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Natera's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.54, Natera faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Natera In The Eyes Of 14 Experts

Bernstein analyst Eve Burstein maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform and raises the price target from $160 to $200.

Bernstein Maintains Outperform on Natera, Raises Price Target to $200

WIIM

Natera shares are trading higher after Canaccord Genuity raised its price target on the stock from $165 to $180.

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $165 to $180.

Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $180

Billionaire investor Stanley Druckenmiller's family office Duquesne has offloaded two of Wall Street's hottest AI stocks – Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), according to a recent 13F filing.
What Happened: Druckenmiller&#8217;s Duquesne Family Office sold all of its Nvidia shares and significantly reduced its Palantir holdings by 95% during the third quarter.
This comes after Nvidia and Palantir have been on a tear this year. While the Nvidia stock surged nearly 190% in 2024 so far, Palantir shares have gained over 386% to date.
While it's not clear why Duquesne has offloaded these two red-hot AI stocks, profit booking could be one of the motives.
Nvidia and Palantir's relatively rich valuations could also have contributed to Duquesne paring its holdings – while Nvidia's trailing 12 months (TTM) price-to-earnings (PE) ratio stands at 55.21, Palantir's stands at 403.45.
Meanwhile, Druckenmiller is increasing his stake in Teva Pharmaceutical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), a company that has seen its shares rise by 112% this year.
Teva&#8217;s strategic shift towards brand-name therapies and its resolution of opioid litigation as key factors contributing to its recent success.
Druckenmiller&#8217;s fund added 1,427,950 shares of Teva during the September-ended quarter, signaling confidence in the pharmaceutical company&#8217;s turnaround and growth potential.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42545656/bitcoin-is-no-manhattan-real-estate-peter-schiff-challenges-microstrategys-micheal-saylor-btc-doesnt-generate-any-income" target="_blank" rel="noreferrer noopener">Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy's Michael Saylor: ‘BTC Doesn't Generate Any Income'</a>
Why It Matters:&nbsp;Druckenmiller, a protégé of&nbsp;George Soros, is renowned for his macroeconomic investment strategy, often making significant bets on industry trends rather than individual companies.
His recent decision to pivot from AI to pharmaceuticals marks a notable shift in his investment focus. Earlier this year, Druckenmiller <a href="https://www.benzinga.com/24/12/42659876/stanley-druckenmiller-pours-funds-into-1-trillion-company-already-trading-up-100">increased his stake</a> in&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), a semiconductor giant, demonstrating his interest in high-growth sectors.
In February, <a href="https://www.benzinga.com/markets/equities/24/02/37175336/billionaire-investor-stanley-druckenmillers-firm-dumps-alphabet-amazon-boosts-investments-in-ai-">Druckenmiller&#8217;s firm divested from</a>&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) while <a href="https://www.benzinga.com/markets/equities/24/02/37175336/billionaire-investor-stanley-druckenmillers-firm-dumps-alphabet-amazon-boosts-investments-in-ai-">bolstering investments in AI leaders</a> like&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and&nbsp;Nvidia.
Despite his bullish stance on AI, Druckenmiller&#8217;s recent actions suggest a <a href="https://www.benzinga.com/general/health-care/24/12/42627207/stanley-druckenmillers-top-holding-has-outperformed-its-sector-by-252">strategic realignment towards</a> the healthcare sector, particularly in companies like&nbsp;Natera Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), which has outperformed its sector significantly.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42495782/crypto-market-predicted-to-surge-to-all-time-highs-by-late-2025-but-a-30-drop-in-bitcoin-prices-could-come-first" target="_blank" rel="noreferrer noopener">Crypto Market Predicted To Surge To All-Time Highs By Late 2025, But A 30% Drop In Bitcoin Prices Could Come First</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

AMZN

AVGO

GOOG

GOOGL

MSFT

PLTR

Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next

Billionaire Stanley Druckenmiller, a former confidant of George Soros and the founder of Duquesne Capital, built his career off making <a href="https://www.benzinga.com/general/24/03/37598371/stanley-druckenmillers-secret-sauce-the-two-stocks-dominating-a-quarter-of-his-three-billion-dollar">large, measured bets</a>. His latest large wager has paid off.
The famed investor has steadily increased his stake in Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a clinical genetic testing company, since the third quarter of 2022, according to quarterly 13F filings. Druckenmiller owned 414,955 shares in 2022&#8217;s third quarter, 893,030 shares in 2023 and 3,566,850 shares in 2024.
Druckenmiller&#8217;s position now exceeds $575 million, nearly 3% of the Austin, Texas-based company&#8217;s market capitalization and 15% of Duquesne Capital&#8217;s portfolio.
Since Duquesne Capital revealed its stake in a 13F filing, its stock has traded up 268%. Meanwhile, the healthcare industry as a whole, as measured by the iShares US Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), has risen a touch over 16%. Thus, Druckenmiller&#8217;s gamble has outperformed its sector by over 250%.
Also Read: <a href="https://www.benzinga.com/markets/equities/24/12/42624528/government-shutdown-threat-stocks-wobble-holiday-travel-and-paychecks-could-face-delays-what-you-need-to-know">Government Shutdown Threat: Holiday Travel, Paychecks Could Face Delays If No Deal Reached</a>
Natera specializes in genetic testing and diagnostics to improve healthcare outcomes. The company develops and markets tests that analyze DNA to provide insights into hereditary conditions, reproductive health, organ transplant health, and oncology. 
Natera's flagship products include non-invasive prenatal tests (NIPTs) like Panorama, which screens for chromosomal abnormalities in a fetus, and Horizon, a carrier screening test for hereditary conditions.
In recent years, Natera has expanded its focus to oncology and organ transplant monitoring. In oncology, the company's Signatera test detects minimal residual disease (MRD) in cancer patients, helping to guide treatment decisions and monitor for recurrence with precision.
In the transplant space, the Prospera test assesses organ health by measuring donor-derived cell-free DNA, providing early indications of transplant rejection.
The company has beaten earnings and revenue expectations over the past four quarters. Revenue has increased from $625 million in 2021 to $1.5 billion over the past twelve months, while margins have also expanded. The company has posted a positive operating cash flow since March.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Health Care

Hedge Funds

iShares Trust Dow Jones US Healthcare Sector Index Fund

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Investors with significant funds have taken a bullish position in Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in NTRA usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 12 options transactions for Natera. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 91% being bullish and 0% bearish. Of all the options we discovered, 11 are puts, valued at $1,304,670, and there was a single call, worth $28,000.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $160.0 for Natera over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Natera options trades today is 137.5 with a total volume of 14,736.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Natera's big money trades within a strike price range of $160.0 to $160.0 over the last 30 days.
<h3>Natera Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734119344_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$160.00</td>
<td>$380.0K</td>
<td align="right">134</td>
<td>1.2K</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.8</td>
<td>$7.3</td>
<td>$7.3</td>
<td>$160.00</td>
<td>$219.0K</td>
<td align="right">134</td>
<td>305</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$160.00</td>
<td>$115.2K</td>
<td align="right">134</td>
<td>1.5K</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.2</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$160.00</td>
<td>$112.5K</td>
<td align="right">134</td>
<td>605</td>
</tr>
<tr>
<td>NTRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.6</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$160.00</td>
<td>$89.7K</td>
<td align="right">134</td>
<td>1.9K</td>
</tr>
</tbody>
</table>

<h3>About Natera</h3>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Current Position of Natera</h3>
<ul>
<li>Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 75 days.</li>
</ul>
<h3>Expert Opinions on Natera</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $192.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Natera, maintaining a target price of $200. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Natera, maintaining a target price of $200. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Natera, targeting a price of $176. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Natera options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Market Whales and Their Recent Bets on NTRA Options

JP Morgan analyst Julia Qin maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $160 to $200.

JP Morgan Maintains Overweight on Natera, Raises Price Target to $200

Natera shares are trading higher. The stock may be moving on continued strength after the company announced yesterday the enrollment of its first patients in SAGITTARIUS, a randomized Phase III clinical trial for colon cancer.

SAGITTARIUS is Natera's first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancer
Approximately 700-900 patients expected to be enrolled across more than 20 sites
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54165644&amp;newsitemid=20241212128799&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=0d1cd45cd5947a2b3f7b0540e214d52b">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinical trial designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients with colon cancer.
The study aims to enroll approximately 700-900 stage III and high-risk stage II colon cancer patients following surgical resection.
<ul>
<li>Signatera-positive patients will be randomized to receive either genotype-guided therapy tailored to their individual tumor mutational profile or six months of standard chemotherapy. The trial's investigational arm will explore the potential of administering immunotherapy or targeted agents approved for metastatic colon cancer earlier in the disease course to increase the proportion of patients cured with adjuvant therapy. This genomically-driven approach will focus on mismatch repair status, POLE, RAS/RAF mutation status, and HER2 amplification status.</li>
<li>For Signatera-negative patients, the trial will compare physician choice treatments with options for de-escalation to observation or single-agent capecitabine for six months.</li>
</ul>
SAGITTARIUS includes collaborations with 9 partners in 5 countries in Europe, and a network of 26 clinical centers in Italy, Spain, and Germany.

Biotech

Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites

Natera Announces Launch Of iPRS For Breast Cancer Risk Assessment

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has fallen 6.33% since its last report. The company recently reported that it has 3.74 million shares sold short, which is 2.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733161520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

Looking Into Natera's Recent Short Interest

Test demonstrated high performance metrics in largest study of its kind in the US with sensitivity of 100% and specificity of 99.3%
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54159522&amp;newsitemid=20241202602532&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=6047985f82cc3e83d1744b37218ceaea">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics &amp; Gynecology (also known as The Green Journal) <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjournals.lww.com%2Fgreenjournal%2Fpages%2Farticleviewer.aspx%3Fyear%3D9900%26issue%3D00000%26article%3D01185%26type%3DFulltext&amp;esheet=54159522&amp;newsitemid=20241202602532&amp;lan=en-US&amp;anchor=published+the+Company%26%238217%3Bs+clinical+validation+study&amp;index=2&amp;md5=671b0289a479c1f3b2bdd02c5348fa1a">published the Company's clinical validation study</a> on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT).
Natera's study is the largest clinical validation of a fetal RhD test performed in the United States to date, with fetal RhD status confirmed via newborn serology in 655 RhD-negative pregnant patients. The study provides compelling scientific evidence on the ability of Natera's Fetal RhD NIPT to identify fetal RhD status, and demonstrates its potential to assist patients and clinicians in the prevention and management of RhD alloimmunization. In addition, Natera's next generation sequencing (NGS)-based Fetal RhD test can identify RHD pseudogene and other hybrid variants that are more commonly occurring in people of non-European ancestries.
Key highlights of the study include:
<ul>
<li>356/356 fetuses were correctly identified as fetal RhD positive (sensitivity: 100% [95% CI: 98.9-100.0]).</li>
<li>Of the 297 RhD-negative fetuses, 295 were correctly identified as RhD-negative (specificity of 99.3% [95% CI: 97.6-99.8]).</li>
<li>Positive predictive value for the test was 99.4% and negative predictive value was &gt;99.9%.</li>
<li>The study included a representative mix of race and ethnicities in the RhD-negative U.S. population.</li>
</ul>
RhD alloimmunization, which can lead to hemolytic disease of the fetus and newborn, can occur when an RhD-negative patient carries an RhD-positive fetus. Historically, this risk is well managed by giving Rho(D) immune globulin therapy (RhIg). However, approximately 40% of patients with an RhD-negative fetus receive this medication unnecessarily. This is particularly important as recent nationwide shortages of RhIg have created an even greater need for testing that allows providers to both prevent alloimmunization and conserve supplies of RhIg, consistent with recent <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.acog.org%2Fclinical%2Fclinical-guidance%2Fpractice-advisory%2Farticles%2F2024%2F03%2Frhod-immune-globulin-shortages&amp;esheet=54159522&amp;newsitemid=20241202602532&amp;lan=en-US&amp;anchor=guidance&amp;index=3&amp;md5=2a0dd926c7ec4a85c18a055b5118c957">guidance</a> from the American College of Obstetricians and Gynecologists (ACOG) supporting cfDNA screening for fetal RhD testing.

Natera Announces That Obstetrics & Gynecology Published The Company's Clinical Validation Study On Its Cell-Free DNA Fetal RhD Noninvasive Prenatal Test

Bernstein analyst Eve Burstein maintained a Buy rating on Natera (NTRA – Research Report) on January 6 and set a price target of $160.00. The compa...

Bernstein Sticks to Their Buy Rating for Natera (NTRA)

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 7. Puneet Souda has given h...

Positive Outlook for Natera: Buy Rating Driven by Strong Revenue Performance and Strategic Developments

Bernstein analyst Eve Burstein maintained a Buy rating on Natera (NTRA – Research Report) today and set a price target of $200.00. The company's sh...

Bernstein Keeps Their Buy Rating on Natera (NTRA)

Reports preliminary FY24 revenue $1.7B, consensus $1.63B. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Natera reports preliminary Q4 revenue $472M, consensus $409.91M

Natera guides Q4 and FY revenue above consensus

In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on Natera (NTRA – Research Report), with a price target of $195.00...

TD Cowen Remains a Buy on Natera (NTRA)

Craig-Hallum raised the firm's price target on Natera (NTRA) to $210 from $174 and keeps a Buy rating on the shares. The firm notes Natera pre-anno...

Natera price target raised to $210 from $174 at Craig-Hallum

In a report released on January 14, Eve Burstein from Bernstein maintained a Buy rating on Natera (NTRA – Research Report), with a price target of ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 14. Puneet Souda has given ...

Natera's Strategic Advancements and Market Positioning Drive Buy Rating

Guggenheim analyst Subbu Nambi raised the firm's price target on Natera (NTRA) to $200 from $170 and keeps a Buy rating on the shares based on the ...

Comments

Natera

Noticias

Últimas noticias sobre Natera (NASDAQ:NTRA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL